Therapy Areas: Respiratory
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA)...
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
30 June 2026 - Grünenthal, a Germany-based pharmaceutical company, announced on Monday that the company has successfully concluded a Phase I trial evaluating the safety and tolerability of its pr...
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
29 June 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq: UTHR) announced on Monday that it has received U.S. Food and Drug Administration premarket approval for the LungFX device,...
bioMérieux files FDA application for rapid vaginitis diagnostic panel
26 June 2026 - French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Friday that it has submitted a Dual 510(k)/CLIA Waiver application to the US Food and Drug Administration ...
Racura Oncology doses first patient in Phase 1 lung cancer trial
26 June 2026 - Australian-based clinical-stage biopharmaceutical company Racura Oncology Limited (ASX:RAC) announced on Thursday that the first patient has been dosed with RC220 in HARNESS-1, a Phase ...
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of second...